Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lagevrio (molnupiravir) is an investigational, orally administered nucleoside analog that accumulates errors in the viral genome leading in inhibition of SARS-CoV-2 replication, the causative agent of COVID-19.
Product Name : Lagevrio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Emergent BioSolutions
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga (Ansuvimab-zykl) in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga...
Product Name : Ebanga
Product Type : Antibody
Upfront Cash : Undisclosed
July 07, 2022
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Emergent BioSolutions
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Treatment for Ebola Virus
Details : The U.S. Food and Drug Administration approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children.
Product Name : Ebanga
Product Type : Antibody
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Formerly known as mAb114, ansuvimab has also been granted Orphan Drug Designation, Breakthrough Therapy Designation and Priority Review Designation as a treatment for Ebola virus disease by the U.S. Food and Drug Administration (FDA).
Product Name : Ebanga
Product Type : Antibody
Upfront Cash : Inapplicable
August 28, 2020
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review designation for Ridgeback’s investigational Ebola treatment, ansuvimab (mAb114).
Product Name : Ebanga
Product Type : Antibody
Upfront Cash : Inapplicable
July 29, 2020
Lead Product(s) : Ansuvimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AGILE will test multiple potential therapeutics, and EIDD-2801 was selected to be the first oral anti-viral to be studied in the AGILE platform.
Product Name : Lagevrio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EIDD-2801 is an oral nucleoside analogue that has demonstrated extraordinarily favorable tolerability in Phase 1 at all doses tested.
Product Name : Lagevrio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2020
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Details : Under terms of the agreement, Merck, through a subsidiary, will gain exclusive worldwide rights to develop and commercialize EIDD-2801 and related molecules.
Product Name : Lagevrio
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 26, 2020
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EIDD-2801 has been shown to treat MERS and SARS (two severe coronavirus infections) in animals when given after an infection has been established.
Product Name : EIDD-2801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2020
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable